Aclaris Therapeutics (ACRS) Price & Analysis

Compare

792 Followers

ACRS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $5.17

Previous CloseN/A

Volume227.82K

Average Volume (3M)1.24M

Market Cap

$193.91M

Enterprise Value$76.62M

Total Cash (Recent Filing)$99.81M

Total Debt (Recent Filing)$2.37M

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Nov 05, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding108,332,214

10 Day Avg. Volume936,064

30 Day Avg. Volume1,235,665

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.40

Enterprise Value/Revenue4.56

Enterprise Value/Gross Profit18.88

Enterprise Value/Ebitda-1.36

Forecast

1Y Price Target

$7.92

Price Target Upside352.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAclaris Therapeutics reported strong proof-of-concept results for its ITK/JAK3 inhibitor in atopic dermatitis with high tolerability and rapid responses.

Product DevelopmentACRS is developing a pair of recently in-licensed antibody assets, indicating continued pipeline progress and potential future growth.

Safety ProfileThe favorable safety profile of ATI-2138, if sustained, is expected to provide a key competitive advantage against approved JAK inhibitors.

Bears Say

Conflicts Of InterestInvestors should be aware of potential conflicts of interest as Wedbush Securities seeks to do business with companies covered in its research reports.

Study Design And Sample SizeCompared to the atopic dermatitis clinical landscape, '2138's treatment effect is competitive, though the study's design and sample size are noted.

Aclaris Therapeutics News

Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)

Reports Q2 revenue $1.78M, consensus $1.29M. As of June 30, 2025, Aclaris had cash, cash equivalents and marketable...

16d ago

ACRS

Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports

In the early hours of the evening session, U.S. equity futures were broadly lower, continuing the regular sessions...

24d ago

CAR

Aclaris announces ATI-2138 trial meets primary, secondary endpoints

Aclaris Therapeutics (ACRS) announced top-line results from its open-label, single-arm Phase 2a trial of ATI-2138 in 14 patients...

24d ago

ACRS

Aclaris Therapeutics CSO Joe Monahan to retire, Roland Kolbeck to succeed

Aclaris Therapeutics (ACRS) announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan,...

26d ago

ACRS

Aclaris Therapeutics Reports Q2 2025 Results and Updates

Aclaris Therapeutics Inc. ( ($ACRS) ) has released its Q2 earnings. Here is a breakdown of the information...

15d ago

ACRS

Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements

Thomas Smith, an analyst from Leerink Partners, maintained the Buy rating on Aclaris Therapeutics. The associated price target...

23d ago

ACRS

Aclaris Therapeutics Announces Positive Phase 2a Trial Results

Aclaris Therapeutics ( ($ACRS) ) just unveiled an update. On July 29, 2025, Aclaris Therapeutics announced the top-line...

24d ago

ACRS

Aclaris Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating and $6 price...

1M ago

ACRS

Aclaris Therapeutics Highlights Clinical Pipeline and Outlook

Aclaris Therapeutics ( ($ACRS) ) has provided an update. On June 30, 2025, Aclaris Therapeutics updated its corporate...

2M ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics (ACRS – Research Report)....

2M ago

ACRS

Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052

Aclaris Therapeutics (ACRS) has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific...

2M ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aclaris Therapeutics (ACRS – Research Report) today and...

2M ago

ACRS

Aclaris Therapeutics Approves 2025 Equity Incentive Plan

Aclaris Therapeutics ( ($ACRS) ) just unveiled an announcement. On June 5, 2025, Aclaris Therapeutics‘ stockholders approved the...

3M ago

ACRS

Aclaris Therapeutics initiates Phase 2 trial of bosakitug

Aclaris Therapeutics (ACRS) announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug in...

3M ago

ACRS

ACRS FAQ

What was Aclaris Therapeutics’s price range in the past 12 months?

Aclaris Therapeutics lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.

What is Aclaris Therapeutics’s market cap?

Aclaris Therapeutics’s market cap is $193.91M.

When is Aclaris Therapeutics’s upcoming earnings report date?

Aclaris Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 74 days.

How were Aclaris Therapeutics’s earnings last quarter?

Aclaris Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.003.

Is Aclaris Therapeutics overvalued?

According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics does not currently pay dividends.

What is Aclaris Therapeutics’s EPS estimate?

Aclaris Therapeutics’s EPS estimate is -0.13.

How many shares outstanding does Aclaris Therapeutics have?

Aclaris Therapeutics has 108,332,214 shares outstanding.

What happened to Aclaris Therapeutics’s price movement after its last earnings report?

Aclaris Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aclaris Therapeutics?

Currently, no hedge funds are holding shares in ACRS

Aclaris Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-101.41%

Trailing 12-Months

Asset Growth

17.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics (ACRS) Earnings & Revenues

Historic Earnings Reports

ACRS Stock 12 Month Forecast

Average Price Target

$7.92

▲(352.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,2.643076923076923,3.756153846153846,4.86923076923077,5.9823076923076925,7.095384615384615,8.208461538461538,9.321538461538461,10.434615384615384,11.547692307692307,12.66076923076923,13.773846153846153,14.886923076923077,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,2.0215384615384617,2.513076923076923,3.0046153846153847,3.496153846153846,3.987692307692308,4.479230769230769,4.970769230769231,5.462307692307692,5.953846153846154,6.445384615384616,6.936923076923077,7.428461538461539,{"y":7.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,1.5276923076923077,1.5253846153846153,1.523076923076923,1.5207692307692309,1.5184615384615385,1.5161538461538462,1.5138461538461538,1.5115384615384615,1.5092307692307692,1.506923076923077,1.5046153846153847,1.5023076923076923,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.15,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >